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related activities in Sp/Rec (p < 0.01). All KOOS subscales were
associated with VAS pain in ExT group (p< 0,0001). The women
of the IIA group demonstrated significant correlations between
stair climbing test and ADL (r = -0.767, n=14, p=0.0014) and
QL (r = -0,744, p= 0.0023).). In the IIB group no correlations
were detected between the results of the functional performance
tests and KOOS. In group III all KOOS subscales had reversal
association (r= -0,247-0,436; p= 0,006-0,00001) with tibiofemoral
osteophytes but not with patellofemaral ones.
Conclusions: 1. The effect of the long-term ExT expressed (out
of 5 subscale of KOOS) moderately in ADL and substantially in
SP/Rec, but also in QL scales.
2. To monitor long-term ExT, it is advisable to fill in the KOOS
questionnaire every month, otherwise the fluctuations but also
relapses occurring meantime remain undetected.
3. In general, after 3 year period without ExT women with early
grades of knee OA had more symptoms and more functional
limitations in SP/Rec activities.
4. All KOOS subscales were associated with tibiofemoral osteo-
phytes at follow-up
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Purpose: The benefit of intra-articular (IA) hyaluronan (HA) in
alleviating the symptoms of osteoarthritis (OA) associated with
other diarthrodial joints other than the knee is of increasing
interest. We performed a pilot study to examine the safety and
efficacy of IA HA in the treatment of ankle OA.
Methods: 30 consecutive patients with ankle OA (documented
by X-ray) were entered into a 12-week double-blind, randomized,
controlled study comparing 5 IA injections of HA 2cc vs saline
(S) 2cc in the tibiotalar joint. The primary outcome variable was
pain relief upon movement and weightbearing using the Ankle
Osteoarthritis Scale (AOS). Additional measures included the
WOMAC, patient global assessment, SF-12 Health Survey, and
all adverse events (AEs).
Results: There were no significant differences between the study
groups in demographics (mean age 50, 90% men, mean BMI 30,
43% with right ankle involvement, 80% with history of trauma,
mean Kellgren-Lawrence grade 2.5, and all with reduced plantar
flexion on range of motion), or baseline assessments (AOS pain
72.3, AOS disability 84.0, WOMAC pain 50.3, WOMAC function
54.0). 80% of the HA and 73% of the S patients completed the
study. Change from baseline to final visit data are presented.
An average of 46% improvement in the AOS pain subscore was
observed in the HA group compared to an 8% in the control.
Despite the numeric superiority of the HA group, there were no
statistical differences except at 3 months.
P313 – Table 1. Statistical Data Found
Groups Pmax2 Peq2 Vmax-Veq Emax Eeq Gmax Geq
(N) (N) (MPa) (MPa) (MPa) (MPa)
PRGF 16 weeks X 27,603* ** 1,277 0,197 25,008* ** 1,790 10,245* ** 0,748
SD 16,487 1,523 0,000 8,196 1,621 3,588 0,677
19 weeks X 44,522* ** 2,987 0,197 37,452* ** 3,099 15,645* ** 1,293
SD 13,875 3,304 0,000 12,692 2,639 5,302 1,103
CONTROL 16 weeks X 59,597* ** 1,073* 0,197 54,572* ** 3,446 22,796* ** 1,439
SD 21,749 0,473 0,000 28,586 3,796 1,941 1,586
19 weeks X 88,680* ** 2,547* 0,197 85,761* ** 3,837 35,843* ** 1,603
SD 16,772 1,260 0,000 20,189 2,843 8,433 1,187
X: median; SD: standard deviation; *p<0,05.
Table 1. Change From Baseline
Treatment AOS AOS WOMAC WOMAC Patient
Pain Disability Pain Function Global
HA -15.0 -21.0 -16.4 -17.0 -1.6
S -5.9 -9.5 -8.8 -5.5 -1.1
The incidence of AEs was low with no significant differences
between groups. There were no post-injection flares.
Conclusions: In this pilot study in OA of the ankle, mostly related
to a significant history of trauma, 5 weekly injections of HA was
a safe with numeric but not statistical superiority over S.
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Purpose: To study the mechanical behaviour of tissue repair
in chondral lesions treated with Plasma Rich in Growth Factors
(PRGF) and to compare with normal cartilage.
Methods: 5mm diameter x 4mm depth lesions was realized
in 12 rabbit’s femoral condyles. The treatment consisted in 7
intraarticular injections of autologous PRGF every two days.
The rabbit’s femoral condyles, of animals euthanized at 16 (6)
and 19 (6) weeks old (5 and 8 weeks after the surgery), were
analyzed. At the same time, another 12 samples (16 and 19
weeks old) from health animals were obtained to compare their
behaviour with PRGF group. Indentation study was made to
get the maximum and equilibrium load (Pmax and Peq) of the
cartilage and tissue repair. The samples received compression
loads, following the method described by Jin and Lewis (2004).
A 0,15 milimeters (mm) depth deformation in 0,15 seconds (s)
was made and it was supported during 1200s. Poisson rate (v),
Young module (E) and Shear module (G) were calculated with the
theoretical model described by Hayes et al. (1972) (Viscoelastic
Lineal Model). Statistical for Windows: ANOVA with p<0,05 was
used to statistical analysis.
Results: The results can be classified in direct results: highest
and equilibrium load; and indirect results: highest and equilibrium
v, E and G. (Table 1).
Conclusions: The tissue repair in PRGF group had a viscoelas-
tic behaviour just like the control group, although the values
of Control group were higher than PRGF group. As the age
increase, the "rigidity" of the both groups was greater with statis-
tical differences between times.
